Regencell Bioscience Holdings (RGC) Announces $5M Insider Share Purchase by CEO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO
May 16, 2022 8:56 AM EDTHONG KONG--(BUSINESS WIRE)-- Regencell Bioscience Holdings Limited (NASDAQ: RGC) (Regencell or the Company), an early-stage bioscience company focusing on the research, development and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting peoples immune system, announced that Yat-Gai Au, the Companys Chairman and CEO, made purchases of ordinary shares in Regencell (Ordinary Shares) totaling $5.03 million.
Based on his Schedule 13D filings with the U.S. Securities and Exchange Commission (the SEC) between July 27, 2021 and May 16, 2022, Mr. Au used an aggregate of $5.03 million of... More
